BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, is highlighting recent ADME-Tox research at the 13th International Meeting of the International Society for the Study of Xenobiotics (ISSX) and 24th International Symposium on Microsomes and Drug Oxidations (MDO). This conference will be held from September 11-14 at the Westin Seattle.
“We are looking forward to meeting with the research community at ISSX,” said Dr. Christopher Black, BioIVT Senior Vice President ADME-Tox. “The ISSX conference is an important event in our year,…
PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes
Cambridge, UK, 06 September 2022: PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced it has entered into a multi-project target discovery collaboration with Roche, one of the world's leading biotechnology companies. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. Further financial terms are not disclosed.
PhoreMost will…
Press release
Macomics to Present at Upcoming Conferences, Q3 2022
Edinburgh and Cambridge, UK, 1 September 2022 - Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to confirm that it will be presenting at a number of upcoming business and scientific conferences, as detailed below.
• Dr Luca Cassetta, co-founder and VP Immunology of Macomics will be attending the 2022 ISEH Annual meeting, Edinburgh, 1-4 September
o Speaking at Q&A session on transition from academia to start up, 2 September
• Dr Steve Myatt, CEO of Macomics, will be…
AMSBIO has published an interview with Professor Marius Wernig from Stanford University, Pathology Stem Cell Institute that discusses what could be the world’s first widely applicable curative treatment for Epidermolysis Bullosa (EB).
This rare genetic disease causes chronic and incredibly painful skin wounds that often lead to an aggressive form of skin cancer and eventual death.
While various cell-therapy approaches have been attempted, Professor Wernig and collaborators identified the need for induced pluripotent stem cells (iPSCs), and how they could become used to treat EB in a more…
The next wave of talent “…are looking for destination locations that align with the values and ethos of the company and often the physical structure that’s in to enable innovation is part of what attracts the best people” Tony Jones, One Nucleus.
Listen to the full podcast with Chris Walters, JLL’s Head of UK Life Sciences and Tony Jones, CEO of One Nucleus where they discussed the importance of destination locations for innovation in life sciences. They covered a range of topics affecting the life sciences sector in the UK including, how destination real estate locations can enable…
The world of life sciences is complex - add insurance requirements into the mix and it can become a very confusing place to be.
Having appropriate insurance and risk management solutions in place can be crucial for any life science business, whether your seeking initial funding, running clinical trials or taking a product to market.
There are many questions that arise – and myths that surround these topics. Here we share some of the most common myths that have been debunked by CFC Underwriting, a specialist insurance provider to the science and technology sectors.
With constant…
Researchers are invited to apply to receive DNA that has been synthesised using Evonetix’s platform
Cambridge, UK 16th August 2022– EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced the opening of its early access program for semiconductor synthesised DNA. Evonetix’s DNA synthesis capability brings together patented semiconductor chip design and proprietary, thermally controlled synthesis chemistry, which will be integral to the Company’s future gene synthesis platforms.
Evonetix’s proprietary process utilises a novel…
16th AUGUST 2022
Designed to efficiently induce differentiation in ES and iPS cells, AMSBIO has expanded its iMatrix series of recombinant laminin E8 fragments to now include isoforms LN-111 and LN-332.
This expanded range of laminin isoforms (LN-111, 332, 511, 411 and 221) now provides even greater flexibility and control when tailoring your substrate to the requirements of specific cultured cells.
Proven in many leading life science research labs - iMatrix is used as a substrate for culturing and maintaining cells, including Pluripotent Stem Cells and Mesenchymal Stem Cells, as well…